Insights Blog
Explore our thought leadership insights, as life science technologies evolve and accelerate.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
.png)
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics | November Round-Up 2025
Read about the latest updates in the Next-Generation Therapeutics space in the month of November.
December 4, 2025
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics | November Round-Up 2025
Read about the latest updates in the Next-Generation Therapeutics space in the month of November.
December 4, 2025
Next-Generation Therapeutics
DeciBio Q&A
Clinical Diagnostics
MRD: Market Reflections in Diagnostics - A Conversation with Dr. Osama Khan, a Staff Pathologist at Natera
We recently interviewed Dr. Osama Khan, a Staff Pathologist at Natera, a personalized genetic testing and diagnostics company.
December 4, 2025
DeciBio Q&A
Clinical Diagnostics
MRD: Market Reflections in Diagnostics - A Conversation with Dr. Osama Khan, a Staff Pathologist at Natera
We recently interviewed Dr. Osama Khan, a Staff Pathologist at Natera, a personalized genetic testing and diagnostics company.
December 4, 2025
MRD Testing
DeciBio Q&A
Financial Services
The Early Wave of AI in Healthcare Belongs to Startups. For Now.
Healthcare went from digital laggard to one of the fastest adopters of applied AI, and we break down why the shift happened and who’s actually benefiting.
December 3, 2025
DeciBio Q&A
Financial Services
The Early Wave of AI in Healthcare Belongs to Startups. For Now.
Healthcare went from digital laggard to one of the fastest adopters of applied AI, and we break down why the shift happened and who’s actually benefiting.
December 3, 2025
AI / Machine Learning
Newsletter Update
Financial Services
Investing in Precision Medicine: VC | PE | M&A - October Round-Up 2025
October 2025 marked a period of intense deal-making across the life sciences, driven by robust financing and aggressive capital plays, primarily focusing on metabolic disease and advanced oncology.
November 19, 2025
Newsletter Update
Financial Services
Investing in Precision Medicine: VC | PE | M&A - October Round-Up 2025
October 2025 marked a period of intense deal-making across the life sciences, driven by robust financing and aggressive capital plays, primarily focusing on metabolic disease and advanced oncology.
November 19, 2025
Precision Medicine
DeciBio Ventures
Private Equity
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | October Round-Up 2025
Liquid Biopsy (LBx) continued to develop through October, featuring new regulatory approvals and partnerships as well as trial launches and study results.
November 13, 2025
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | October Round-Up 2025
Liquid Biopsy (LBx) continued to develop through October, featuring new regulatory approvals and partnerships as well as trial launches and study results.
November 13, 2025
Liquid Biopsy
DeciBio Q&A
Clinical Diagnostics
Current Perspective on Comprehensive Genomic Testing - Q&A with Premal Shah, Ph.D., CEO at MyOme
We recently interviewed Premal Shah, Ph.D., CEO of MyOme, a precision health company providing whole‑genome sequencing testing for proactive risk assessments, alongside clinical diagnostics offerings.
November 13, 2025
DeciBio Q&A
Clinical Diagnostics
Current Perspective on Comprehensive Genomic Testing - Q&A with Premal Shah, Ph.D., CEO at MyOme
We recently interviewed Premal Shah, Ph.D., CEO of MyOme, a precision health company providing whole‑genome sequencing testing for proactive risk assessments, alongside clinical diagnostics offerings.
November 13, 2025
Genomics Market
Precision Medicine is evolving at a rapid pace
Discover how we can help
Get in Touch
© DeciBio 2023 | All rights reserved